During the last budget period, the Cancer Center has introduced sweeping changes that affected its administrative infrastructure, decision-making process, scientific realignment of Programs and Shared Resources and expansion of educational and mentoring activities. These changes were directed by a comprehensive, inclusive and transparent strategic planning process that involved all scientific, administrative and educational stakeholders in the Cancer Center. A combination of internal Center-wide consultative sessions, including annual scientific and planning retreats, and in-depth feedback by a newly configured Cancer Center External Advisory Board, contributed to make the strategic planning process a successful endeavor, creating a set of strategic directives {Strategic comparatives) that guided the comprehensive reorganization of the Cancer Center during the last budget period. The resulting 2012 Cancer Center Strategic Plan refined the Center's long-term vision in the continuum of basic, translational and patient-oriented research, streamlined operation and decision-making, and identified concrete opportunities for scientific expansion, thematic faculty recruitment and development of new, multidisciplinary research themes. Overall, the consultative tools that enabled the strategic planning process will continue to provide a fundamental asset for the Cancer Center in the next budget period, ensuring a nimble and research-oriented administrative infrastructure, opportunity-driven decision-making, comprehensive feedback from external advisors and dynamic refinement of research priorities and scientific themes. Building on the successful growth ofthe Cancer Center in the last project period in terms of collaborative contributions and cancer-focused research funding, these planning and consultative processes as supported by the CCSG budget will continue to play an indispensable role in further advancing the cancer research agenda during the upcoming faculty and facility expansion.

Public Health Relevance

The Cancer Center has developed a comprehensive, all-encompassing consultative platform ideally positioned to chart new research directions, identify opportunities for multidisciplinary and collaborative science and guide the process of scientific discovery along the continuum of basic, translational and patient oriented cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-47
Application #
9033842
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
47
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74

Showing the most recent 10 out of 741 publications